Product Description
For Type 2 Diabetes
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Type 2 Diabetes
Phase 1: Type 2 Diabetes|General Diabetes|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2009-011589-27 | P2 |
Completed |
Type 2 Diabetes |
2010-12-02 |
|
S337.2.001 | P2 |
Completed |
Type 2 Diabetes |
2010-12-01 |
|
S337.1.005 | P1 |
Completed |
Healthy Volunteers|General Diabetes |
2010-10-01 |
|
S337.1.002 | P1 |
Completed |
Type 2 Diabetes |
2009-07-01 |